Zoetis Inc., a leading animal-health company, continues to be a point of interest in the financial markets. Despite a bleak outlook that recently led to a slump in the firm’s stock price, Zoetis remains a target for numerous asset management firms. HSBC reduced its price target from $180 to $140 but maintained its 'buy' rating. Similarly, Barclays assigned the company an 'equal-weight' rating with a $136 target. In contrast, Stifel lowered Zoetis' PT to $130, maintaining a ‘hold’ due to the company's ambitious 2026 revenue outlook.
Investors are intrigued by the potential of Zoetis' innovation engine, as well as the company’s product approvals from Health Canada and the European market. The EU approval of Lenivia for canine osteoarthritis pain, as well as the positive opinion for Portela therapy in Europe, has engendered fresh investor interest. The firm's dividend policies are another point of interest, with Zoetis announcing an increased dividend of $0.53 per share and a 6% payment increase for Q1 2026. These developments herald a strong innovation strategy and solid financial prospects, despite stock market turbulence.
Zoetis ZTS News Analytics from Wed, 21 May 2025 07:00:00 GMT to Sat, 13 Dec 2025 16:38:25 GMT - Rating 1 - Innovation 7 - Information 6 - Rumor -5
